SCHEMBL22200440

SCHEMBL22200440

COCCn1c(=O)c(-c2ccc(NSCc3ccccc3F)c(F)c2)cc2cnc(SC)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
HTT P42858 1/20 0.42
STK4 Q13043 3/20 0.40
STK3 Q13188 3/20 0.40
SIK2 Q9H0K1 3/20 0.40
STK26 Q9P289 3/20 0.40
STK24 Q9Y6E0 3/20 0.40
SRC P12931 2/20 0.40
BTK Q06187 1/20 0.40
CYP1A2 P05177 9/20 0.38
HSD17B10 Q99714 8/20 0.38
CYP3A4 P08684 8/20 0.38
TSHR P16473 2/20 0.38
TP53 P04637 2/20 0.37
CYP2C9 P11712 6/20 0.36
USP2 O75604 3/20 0.36
RIPK2 O43353 1/20 0.36
ACVR1 Q04771 1/20 0.36
NOD2 Q9HC29 1/20 0.36
CASP1 P29466 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356454 0.86 ERN1 (0.44) ALDH1A1HTTSTK4STK3SIK2
SCHEMBL22191284 0.86 ERN1 (0.44) ALDH1A1HTTSTK4STK3SIK2
SCHEMBL22200566 0.85 ERN1 (0.40) HTTSRCBTKTSHRERN1
SCHEMBL22200391 0.82 ERN1 (0.35) HTTSRCBTKTSHRTP53
SCHEMBL29353887 0.80 CYP1A2 (0.44) ALDH1A1STK4STK3SIK2STK26
SCHEMBL22191244 0.80 CYP1A2 (0.44) ALDH1A1STK4STK3SIK2STK26
SCHEMBL22200645 0.79 SRC (0.38) STK4STK3SIK2STK26STK24
SCHEMBL22190923 0.77 ERN1 (0.38) STK4STK3SIK2STK26STK24
SCHEMBL29355885 0.77 ERN1 (0.38) STK4STK3SIK2STK26STK24
SCHEMBL25035385 0.75 BRAF (0.45) ALDH1A1HTTSTK4STK3SIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed